Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astria Therapeutics Inc ATXS

Healthcare Biotechnology
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a... see more

Recent & Breaking News (NDAQ:ATXS)

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Business Wire May 24, 2024

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Business Wire May 23, 2024

Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Business Wire May 9, 2024

Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting

Business Wire May 8, 2024

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 2, 2024

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

Business Wire April 9, 2024

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 3, 2024

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

Business Wire March 25, 2024

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 5, 2024

Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Business Wire March 4, 2024

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting

Business Wire February 20, 2024

Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference

Business Wire February 6, 2024

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 5, 2024

Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering

Business Wire January 30, 2024

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 4, 2023

Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress

Business Wire November 27, 2023

Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference

Business Wire November 21, 2023

Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Business Wire November 13, 2023

Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Business Wire November 10, 2023

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

Business Wire November 9, 2023